Sternicki Louise M, Poulsen Sally-Ann
Institute for Biomedicine and Glycomics, Griffith University Gold Coast Queensland 4222 Australia
School of Environment and Science, Griffith University Brisbane Queensland 4111 Australia.
RSC Med Chem. 2025 Jul 30. doi: 10.1039/d5md00617a.
As therapeutic modalities increasingly diversify, the need for biophysical tools for routine characterisation of the underlying biomolecular targets and their noncovalent interactions is growing. In this Opinion article we discuss the role of native mass spectrometry (nMS), a mass spectrometry technique where the intact biomolecule and its noncovalent interactions are preserved during the analysis, to gain important insights to guide drug discovery and development. We conclude that nMS is one of the most powerful technologies available with potential to rapidly advance multiple stages of therapeutic discovery and development, yet it is arguably underutilised. Specifically, we highlight how nMS may progress research for contemporary therapeutic modalities including those implicated in targeted protein degradation, fragment-based drug discovery and mRNA therapies.
随着治疗方式日益多样化，对用于常规表征潜在生物分子靶点及其非共价相互作用的生物物理工具的需求也在不断增长。在这篇观点文章中，我们讨论了原生质谱（nMS）的作用，这是一种质谱技术，在分析过程中完整的生物分子及其非共价相互作用得以保留，从而获得重要见解以指导药物发现和开发。我们得出结论，nMS是可用的最强大技术之一，有潜力快速推进治疗发现和开发的多个阶段，但它可能未得到充分利用。具体而言，我们强调了nMS如何推动当代治疗方式的研究，包括那些涉及靶向蛋白降解、基于片段的药物发现和mRNA疗法的研究。
